Free Submission Public Relations & NewsPR-inside.com
 
DeutschEnglish

Get the latest news
with our RSS feed
rss feed
Add to My Yahoo!
More information
Health
OTC Healthcare in Brazil to 2010

OTC Healthcare in Brazil to 2010 - New Research Report on Companies and Markets


Print article Print article
Refer this article Refer to a friend
© companiesandmarkets.com
2008-07-04 20:45:19 - www.companiesandmarkets.com adds new report - OTC Healthcare in Brazil to 2010

www.companiesandmarkets.com/Summary-Market-Report/OTC-Healthcare ..
Introduction

This databook is a detailed information resource covering all the key data points on OTC Healthcare in Brazil. It includes comprehensive value volume segmentation and market share data. The databook supplies actual data to 2005 and full forecasts to 2010.



Scope

Contains information on:Analgesics,Cough & cold,Indigestion,Medicated skin products,Traditional medicines,Vitamins & Other OTC healthcare products.
Provides market value, volume,

expenditure and consumption data by market, segment and subsegment.
Includes company and brand share data by category, as well as distribution channel data.
Contains market value segmentation by demographic and socioeconomic group.


Highlights

The market for OTC Healthcare in Brazil increased between 2000-2005, growing at an average annual rate of 8%.



The leading company in the market in 2005 was GlaxoSmithKline Plc. The second-largest player was Novartis AG with Pfizer Inc in third place.



Reasons to Purchase

Discover the major quantitative trends affecting the OTC Healthcare markets.
Understand consumers´ consumption and expenditure patterns.
Understand the future direction of the market with reliable historical data and full five year forecasting.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: 07813 784393

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.


Terms & Conditions | About us | Contact PR-inside.com